Today, Axsome Therapeutics announced that the first patient has been dosed with AXS-12 for Narcolepsy in the phase 3 clinical trial known as SYMPHONY. The expected completion, and readout of this clinical trail, will be in the first half of 2023.
Thursday, September 16, 2021
AXS-07 for Acute Migraine
On Tuesday September 14th, Axsome Therapeutics announced that the New Drug Application of AXS-07 for acute migraine, has been accepted by the FDA, which has a PDUFA decision date of April 22, 2022. That's great news for the company and migraine sufferers. If approved, we could see the product on the market mid-year 2022.
Wednesday, September 8, 2021
Ethereum Price Target Reached
Ethereum (ETH) reached it's price target of 3900, then sold off hard. What do the charts suggest now? Corrections occur and are healthy for stocks or indexes. ETH has more than doubled in price in a very short period of time, from a low of around 1,700 to a high of 4,000, which is quite extreme. From the chart below, the previous consolidation area which runs from 2900 to 3400 should act as support for the recent pull-back. If that support is broken to the downside, then I would view that as negative sign, as Ethereum will have to find support at a lower price. Bottom line, the chart is still bullish, but expect some time to pass at this consolidation area, before another move higher. Thank you for reading. 
Subscribe to:
Posts (Atom)